Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark.
Sci Adv. 2023 Jul 21;9(29):eadi4862. doi: 10.1126/sciadv.adi4862.
Nicotinamide riboside is a precursor to the important cofactor nicotinamide adenine dinucleotide and has elicited metabolic benefits in multiple preclinical studies. In 2016, the first clinical trial of nicotinamide riboside was conducted to test the safety and efficacy of human supplementation. Many trials have since been conducted aiming to delineate benefits to metabolic health and severe diseases in humans. This review endeavors to summarize and critically assess the 25 currently published research articles on human nicotinamide riboside supplementation to identify any poorly founded claims and assist the field in elucidating the actual future potential for nicotinamide riboside. Collectively, oral nicotinamide riboside supplementation has displayed few clinically relevant effects, and there is an unfortunate tendency in the literature to exaggerate the importance and robustness of reported effects. Even so, nicotinamide riboside may play a role in the reduction of inflammatory states and has shown some potential in the treatment of diverse severe diseases.
烟酰胺核糖是重要辅酶烟酰胺腺嘌呤二核苷酸的前体，在多项临床前研究中显示出代谢益处。2016 年，进行了首例烟酰胺核糖的临床试验，以测试其对人体补充的安全性和有效性。此后，许多临床试验旨在描绘其对人体代谢健康和严重疾病的益处。本文综述旨在总结和批判性评估 25 篇目前已发表的关于人体烟酰胺核糖补充的研究文章，以确定任何没有充分依据的说法，并协助该领域阐明烟酰胺核糖的实际未来潜力。总的来说，口服烟酰胺核糖补充剂几乎没有显示出明显的临床相关效果，而文献中存在夸大报告效果的重要性和稳健性的不幸趋势。即便如此，烟酰胺核糖可能在减轻炎症状态方面发挥作用，并在治疗多种严重疾病方面显示出一定的潜力。
